Gilead to donate 1.5M doses of remdesivir to treat COVID-19 patients
Category: #health  By Mateen Dalal  Date: 2020-04-06
  • share
  • Twitter
  • Facebook
  • LinkedIn

Gilead to donate 1.5M doses of remdesivir to treat COVID-19 patients

Gilead Sciences, Inc., an American biotechnology company, has recently announced its plan to donate 1.5 million doses of the investigational drug, remdesivir. These 1.5 million doses will be used for over 140,000 treatment courses among coronavirus infected patients, depending on the treatment duration.

According to a statement made by Daniel O’Day, Chief Executive Officer and Chairman at Gilead Sciences, the antiviral drug has been supplied for compassionate use, clinical trials, as well as expanded access. The drug was initially developed by the company for the potential treatment of Marburg and Ebola viruses.

He added that the supply of this drug has been intended to treat patients with severe symptoms, who will receive it intravenously at the hospital on daily basis. He further added that several other clinical trials for the drug are being conducted worldwide, with thousands of COVID-19 patients reportedly participating.

The results from the trials of the investigational and unapproved drug as well as the related adverse effects are still unknown. O’Day further added that the company will significantly cater to the rising concerns and emergency posed by this pandemic by supplying the drug for free, in order to facilitate greater access to patients as soon as possible.

More than 1,700 patients have participated in the treatment programs by adopting the company’s remdesivir on a compassionate drug use basis for pregnant women and children. Sterile manufacturing capabilities, scarce raw materials, multiple chemical reactions, as well as specialized chemistry are essential for producing the drug effectively. The company also has managed to reduce the timeline of the end-to-end manufacturing of remdesivir from nearly a year to roughly 6 months, as well as aimed to deliver the treatment courses of more than 500,000 by October and eventually reach 1 million by 2020 end.

Sources familiar with the matter have reported that nearly 1,252,265 positive cases for the coronavirus have been confirmed across the globe, with over 68,147 deaths. On the other hand, around 238,675 patients have recovered from the disease.

Source credit:

https://finance.yahoo.com/news/gilead-donate-1-5m-doses-200307154.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

NHS requests urgent donations of blood plasma from COVID-19 survivors
NHS requests urgent donations of blood plasma from COVID-19 survivors
By Mateen Dalal

According to reliable sources, United Kingdom National Health Service (NHS) has filed an appeal to the individuals recuperated from novel coronavirus to donate blood plasma. The organization apparently intends to treat the people who get infected dur...

OSE Immunotherapeutics receives $228,000 to develop COVID-19 vaccine
OSE Immunotherapeutics receives $228,000 to develop COVID-19 vaccine
By Mateen Dalal

The novel coronavirus outbreak has turned out to be one of the worst disasters the world has witnessed in recent times. At times like this, pharmaceutical companies worldwide have been putting their best foot forward to find the vaccine for COVID-19....

Singapore’s ESR and Sabana REIT propose merger amid pandemic
Singapore’s ESR and Sabana REIT propose merger amid pandemic
By Mateen Dalal

Although the economic impact of the ongoing COVID-19 has significantly impacted prospects for Singapores REITs (Real Estate Investment Trusts), it seems that some resilient spots in the real estate sector will remain where they were. In the latest st...